You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Factor Xa inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Atrial Fibrillation, Anticoagulant-induced Bleeding Trial in Seoul (Factor Xa Inhibitor)

Recruiting
  • Atrial Fibrillation
  • Anticoagulant-induced Bleeding
  • Factor Xa Inhibitor
  • Seoul, Jongno-gu, Korea, Republic of
    Seoul National university Hostpital
Apr 5, 2023

Contrast Agents and Oral Factor Xa Inhibitor Trial in Bursa (computerized tomography)

Completed
  • Contrast Agents and Oral Factor Xa Inhibitor
  • computerized tomography
  • Bursa, Turkey
    Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Oct 27, 2020

Coagulation Disorder Trial (PROTHROMPLEX TOTAL, 4F-PCC)

Not yet recruiting
  • Coagulation Disorder
  • (no location specified)
Jul 14, 2022

Health Care Interventions and Outcomes of Major Bleedings in

Not yet recruiting
  • Major Bleeding
  • None (Observational study)
  • (no location specified)
Nov 17, 2023

AORTIC VALVE DISEASES, Thromboembolism Trial in Korea, Republic of (Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin))

Recruiting
  • AORTIC VALVE DISEASES
  • Thromboembolism
  • Rivaroxaban Oral Tablet
  • Vitamin K antagonist(warfarin)
  • Bucheon, Korea, Republic of
  • +8 more
Oct 11, 2022

Urgent Surgery Trial (Andexanet alfa, Usual Care)

Not yet recruiting
  • Urgent Surgery
  • Andexanet alfa
  • Usual Care
  • (no location specified)
Jun 21, 2023

Dose Adjustment of Enoxaparin in ICU Patients Trial in Kfar Saba (Dose adjustment of Enoxaparin in patients with sub-therapuetic

Completed
  • Dose Adjustment of Enoxaparin in ICU Patients
  • Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
  • Kfar Saba, Israel
    Meir Medical Center
Jan 23, 2022

Outcomes in Hospitalised Patients Treated With Ondexxya

Not yet recruiting
  • Hemorrhage
  • Andexanet alfa
  • (no location specified)
Jun 12, 2023

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular

Completed
  • AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
  • Wenzhou, Zhejiang, China
    The First Affiliated Hospital of Wenzhou Medical University
Nov 6, 2023

Hemophilia Trial (Coagulation Factor VIIa (Recombinant))

Not yet recruiting
  • Hemophilia
  • Coagulation Factor VIIa (Recombinant)
  • (no location specified)
Jan 12, 2023

Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in

Not yet recruiting
  • Rheumatoid Arthritis
  • Observation
  • (no location specified)
Oct 8, 2022

Is Anti-Factor Xa Associated With Outcome in Critical COVID-19

Completed
  • Covid19
  • +2 more
  • The effect of LMWH
  • Monitoring frequency of aFXa-levels
  • Stockholm, Sweden
    Södersjukhuset
Feb 24, 2022

Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia Trial (HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5%

Not yet recruiting
  • Acneiform Eruption Due to Chemical
  • +2 more
  • HT-001 2% Topical Gel
  • +3 more
  • (no location specified)
Dec 3, 2022

Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier

Completed
  • Arthritis Rheumatoid
  • New York, New York
    Pfizer
Jun 8, 2022

Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and

Unknown status
  • Anticoagulation
  • +2 more
  • Estimated anticoagulant level (conversion factor x anti-Xa activity)
  • (no location specified)
Nov 30, 2020

Immunogenicity of TNF Inhibitors in Arthritis Poorer Treatment

Recruiting
  • Arthritis, Rheumatoid
  • +2 more
    • Aalborg, Denmark
      Department of rheumatology
    Sep 1, 2022

    Hemophilia A, Hemophilia B Trial in Korea, Republic of, South Africa, Taiwan (marstacimab)

    Recruiting
    • Hemophilia A
    • Hemophilia B
    • Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
    • +3 more
    Jan 18, 2023

    Skin Health and Quality of Life in Patients Receiving

    Not yet recruiting
    • Lung Cancer
    • +7 more
    • EQ-5D-5L questionnaire
    • +2 more
    • Roma, Italy
      Roberto Iacovelli
    May 17, 2023

    Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII Trial in United Kingdom, United States (Valoctocogene

    Recruiting
    • Hemophilia A With Inhibitor
    • Hemophilia A With Anti Factor VIII
    • Valoctocogene roxaparvovec
    • Los Angeles, California
    • +4 more
    Aug 2, 2022

    Anti-citrullinated Protein Antibody Status on Treatment Response

    Completed
    • Rheumatoid Arthritis
    • Non-Interventional
    • Canberra City, Australia
      (unnamed)
    Feb 22, 2022

    Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency Trial in China (SS109)

    Recruiting
    • Hemophilia A With Inhibitor
    • +2 more
    • SS109
    • Hefei, Anhui, China
    • +9 more
    Jan 12, 2023

    Hemophilia A Trial in Metairie, New Orleans (Factor IX)

    Recruiting
    • Hemophilia A
    • Factor IX
    • Metairie, Louisiana
    • +1 more
    Nov 14, 2022

    Ondexxya for Intravenous Injection 200mg Drug Use Result

    Recruiting
    • Life Threatening Bleeding
    • Factor Xa Inhibitor
      • Tokyo, Japan
        Research Site
      Jul 7, 2022

      Hemophilia A With Inhibitors, Hemophilia B With Inhibitors Trial in Worldwide (Coagulation FVIIa (Recombinant))

      Completed
      Has Results
      • Hemophilia A With Inhibitors
      • Hemophilia B With Inhibitors
      • Coagulation FVIIa (Recombinant)
      • Aurora, Colorado
      • +8 more
      Feb 24, 2022

      Covid19 Trial in Austin (Enoxaparin, Rivaroxaban)

      Completed
      • Covid19
      • Austin, Texas
        St. David's Medical Center
      Jun 28, 2021